Navigation Links
Sangart, Inc. Completes Series F Funding Round
Date:3/12/2009

des of research into the mechanisms of oxygen transport by cell-free hemoglobin solutions at the Letterman Army Institute of Research and University of California at San Diego. The discoveries arising from this research on the effective action of oxygen therapeutics have been patented and published in numerous scientific articles and form the basis for Sangart's technologies.

To learn more about Sangart, please visit the company's website at www.sangart.com.

    Media Contact:
    Marissa Green
    Edelman Public Relations     Office: 323-202-1463
    Marissa.Green@edelman.com    Cell: 917-345-3684


'/>"/>
SOURCE Sangart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
2. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
3. Cardium Completes $3.5 Million Credit Facility
4. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
5. Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia
6. CIRM Completes Briefing Visit to Stemedica Cell Technologies
7. INVO Bioscience Completes Reverse Merger
8. Particle Sciences Completes Development of First Product Incorporating its Unique Surface Modification System
9. Mach One Corporation Completes Acquisition of Ceres Organic Harvest, Inc.
10. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
11. New Generation Biofuels Completes Construction of Baltimore Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... N.J. , Sept. 22, 2014  WIRB-Copernicus ... and ethical review services for clinical research, announced ... (WIRB) has been reaccredited by the Association ... (AAHRPP), which endeavors to improve safeguards for clinical ... Donald A. Deieso , Ph.D., commented, "It ...
(Date:9/22/2014)... , Sept. 22, 2014 Synageva ... ), a biopharmaceutical company developing therapeutic products for ... Robert Bazemore as Chief Operating Officer.  Reporting ... and Chief Executive Officer, Robert will oversee the ... program, sebelipase alfa for LAL Deficiency, and will ...
(Date:9/21/2014)... For the first time, scientists have discovered how to ... strength and stiffness greater than that of today,s strongest ... a research team led by John V. Badding, a ... published in the 21 September 2014 issue of the ... point of view, our discovery is intriguing because the ...
(Date:9/20/2014)... HealthTronics, Inc. , a ... products and services, has signed a distribution agreement ... Corporation for its high precision laser technology. ... invasive, mobile, surgical technology—offering more choices for healthcare ... HealthTronics will make available Clinicon’s FDA-cleared SureLase™ CO2 ...
Breaking Biology Technology:Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3
... Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS;, ... next,generation of monoclonal antibodies based on its Dynamic ... and Chairman, will,present at the 7th Annual BIO ... Morhet,s thirty-minute presentation to potential investors and,industry partners ...
... Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET), NOVATO, Calif., Oct. 28 , ... Q3 2008 ... 190.5% increase Naglazyme Net Product Revenue ... Aldurazyme Net Sales by Genzyme $38.2 ...
... ASA (OSL:DIAG),today announced that it has signed ... panEuropean provider of gene expression-based,diagnostic testing and ... marking scheduled in early2009, DiaGenic will be ... Europe its innovative blood-based,gene-expression diagnostic test for ...
Cached Biology Technology:InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum 2BioMarin Announces Third Quarter 2008 Financial Results 2BioMarin Announces Third Quarter 2008 Financial Results 3BioMarin Announces Third Quarter 2008 Financial Results 4BioMarin Announces Third Quarter 2008 Financial Results 5BioMarin Announces Third Quarter 2008 Financial Results 6BioMarin Announces Third Quarter 2008 Financial Results 7BioMarin Announces Third Quarter 2008 Financial Results 8BioMarin Announces Third Quarter 2008 Financial Results 9BioMarin Announces Third Quarter 2008 Financial Results 10BioMarin Announces Third Quarter 2008 Financial Results 11BioMarin Announces Third Quarter 2008 Financial Results 12Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests 2
(Date:9/22/2014)... In 2011 the Society of Environmental Toxicology and ... to identify and prioritize the scientific research needed to ... (PPCPs) in the environment. The effort was extended, ... of the Society,s international journal, Integrated Environmental Assessment ... accompanied by a podcast interviewing the lead author of ...
(Date:9/22/2014)... 22, 2014)The Brain & Behavior Research Foundation ... NARSAD Young Investigator Grants valued at more ... world,s most promising young scientists. Recipients of ... research will seek to identify causes, improve ... disorders that affect one in four people, ...
(Date:9/22/2014)... 22, 2014) Additive manufacturing (AM), or 3D ... production of complex-shaped metal components strong enough for ... errors and distortions, as well as quality standards ... pace with the technology. Engineers at the University ... to develop enhanced modeling and simulation (M&S) technology ...
Breaking Biology News(10 mins):Priorities for research on pharmaceutical and personal care products in the environment 2Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2Pitt engineers receive grants to enhance additive manufacturing 2Pitt engineers receive grants to enhance additive manufacturing 3
... 30, 2013 /PRNewswire-iReach/ -- Clinilabs, a contract research organization ... to industry, announced today that they have begun a ... for Type 2 Diabetes Mellitus.  The study is being ... daily doses of the investigational medication over periods of ...
... the University of Wisconsin-Madison have made a discovery that, ... may contribute to diseases like Alzheimer,s and Parkinson,s, which ... the brain. With proteins, shape is everything. The ... molecules about a cell, others to provide essential cellular ...
... laboratory work allowed a diverse team of University of Pittsburgh ... Nature Cell Biology that they had solved the mystery ... By discovering a mechanism by which mitochondria tiny structures ... they are damaged and need to be eliminated, the Pitt ...
Cached Biology News:Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication 2Zinc, proteins, and an essential cellular balancing act 2When cells 'eat' their own power plants; Pitt scientists solve mystery of cellular process 2When cells 'eat' their own power plants; Pitt scientists solve mystery of cellular process 3
...
... Immunogen: Synthetic peptide derived from the ... mouse dog and orangutang occludin proteins. ... occludin protein. Reactivity: Human (positive ... with rat mouse dog and orangutang ...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Biology Products: